Brij Kishore Sharma

Brij Kishore Sharma

Auto-generated profile, based on publicly available information

Brij Kishore Sharma

Department of Chemistry, Government College, University of Kota, Bundi, 323 001, Rajasthan, India

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2025 in Current Pharmaceutical Design
Verified
Journal Article
Closed access
PDF file
SSSmriti Sharma
Smriti Sharma
SCShahista Chuhann
Shahista Chuhann
BSBrij Kishore Sharma
Brij Kishore Sharma
Background: The well-known histamine H3 receptor antagonists are based on an imidazole scaffold. However, the interaction between hepatic CYP450 and imidazole-based drugs leads to some side effects, such as low potential, physicochemical problems, etc. Therefore, another category of chemical class, benzimidazolone has been explored as an antihistaminic H3 agent. Objectives: In this study, the histamine H3 binding affinity of benzimidazolone derivatives has been quantitatively investigated using Dragon descriptors. Methods: The models were developed from statistically corroborated quantitative structure-activity relationship (QSAR) models that delivered rationales for the description of the binding affinity of benzimidazolonebased derivatives. In addition, the identified descriptors through CP-MLR analysis for the histamine H3 binding affinity highlighted the role of symmetry, atomic mass, information content, electrostaticity, rings in the structures, number of chlorine atoms (nCL), and average valence connectivity index chi-3 (X3Av). Results: The PLS assessment validated the power of CP-MLR-identified descriptors. The applicability domain suggested that the model fulfills the superior feature parameters with good fit and predictive power. Conclusion: All the compounds were found to be within the applicability domain of the recommended models.

1 July 2024 in Current Signal Transduction Therapy
Verified
Journal Article
Closed access
PDF file
PPPradeep Pilania
Pradeep Pilania
SNSisir Nandi
Sisir Nandi
DMDinesh Kumar Meena
Dinesh Kumar Meena
BSBrij K. Sharma
Brij K. Sharma
Regulation of cell proliferation depends on stimulatory and inhibitory factors that act in a coordinated manner in response to external signals. Various agents, including mitogens, growth factors, cytokines, and other external factors, can impact the mitotic cell cycle, resulting in either provoking growth, differentiation, or apoptosis. Many kinases, such as protein kinases, regulate mitotic cell proliferation through normal signalling. One of the major protein kinase family members is cyclin-dependent kinases (CDK), which are responsible for the regulation of cell cycle progression. If the cell cycle-regulatory mechanisms are permanently altered, it can cause abnormal proliferation that leads to neoplasia. This can result in tumour development, where the availability and expression of CDKs become altered, contributing significantly to impaired cell proliferation. Changes like these are often a characteristic of cancer. CDK inhibitors have shown significant clinical benefits in treating various types of tumours in recent years. The output has been achieved by the clinical approvals of particular CDK inhibitors. Researchers have also been studying the proteolysis-targeting chimera (PROTAC) molecule for the last two decades. This molecule uses ubiquitin-mediated proteasome mechanisms to break down specific targets, making it a promising method for targeted protein degradation (TPD). TPD has become a promising therapeutic option for tackling disease-causing proteins that are otherwise challenging to treat using traditional small molecules. This review provides an overview of the state of knowledge and a general understanding of selective or nonselective CDK inhibitors and PROTAC degraders currently under development or clinically approved congeners, focusing on improving cancer therapy.


27 October 2026 in Current Pharmaceutical Design
Verified
Journal Article
Closed access
ANAfreen N
Afreen N
BSBrij K. Sharma
Brij K. Sharma
SSSmriti Sharma
Smriti Sharma
MVMurugesan Vanangamudi
Murugesan Vanangamudi
Introduction: Tuberculosis (TB) is a transmissible disease caused by Mycobacterium tuberculosis, which continues to be a major public health issue worldwide. The situation has become more alarming with the increasing cases of multidrug-resistant (MDR) strains, which makes treatment difficult. Nitrofurans, a class of heterocyclic compounds known for their antimicrobial potential, have gained renewed attention as scaffolds for anti-TB drug design. This study aimed to investigate the structural features governing the antitubercular activity of 5-nitrofuranyl derivatives using 2D-QSAR modeling and molecular docking analysis and to identify new compounds that inhibit the biosynthesis of the Mycobacterium tuberculosis cell wall. Method: Twenty-eight 5-nitrofuranyl derivatives were studied by means of 2D-QSAR analysis employing descriptors from the Dragon software suite within the framework of CP–MLR methodology. Statistically significant models were selected based on r², Q² (LOO and L5O), and test set predictivity. Molecular docking was performed using AutoDock Vina against Galactofuranosyltransferase 2 (GlfT2), a validated target involved in the cell wall biosynthesis of M. tuberculosis. Result: Robust QSAR models were obtained with up to R² = 0.912 and Q²LOO = 0.839. Key descriptors influencing activity included topological descriptors (IC1, JGI2, JGI5), mass-weighted Burden eigenvalues (BELm2, BELm6), molecular weight (MW), and selected atom-centered fragments such as C-006 and C-031. Docking studies revealed that several compounds (notably 27, 25, and 3) exhibited high binding affinity to GlfT2 (−9 to −6.7 kcal/mol), correlating well with QSAR predictions. Discussion: The obtained QSAR parameters suggested the importance of molecular topology, electronic features, and particular structural fragments in modulating antitubercular activity. Molecular docking to the GlfT2 protein showed that the binding affinity of compounds 27, 25, and 3 was found to be more favorable for their binding in the active site of the enzyme. Moreover, the results from the ADME study demonstrated that compound 3 acquired the best pharmacokinetic properties compared to the other molecules. Conclusion: This integrated QSAR and molecular modeling study highlights the structural determinants of 5- nitrofuranyl-based antituberculosis agents. Compounds with favorable descriptor profiles and strong GlfT2 binding affinity represent promising leads for further development. This approach demonstrates the effectiveness of combining ligand- and structure-based strategies for rational antitubercular drug design.